Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

/PRNewswire/ — Intensity Therapeutics, Inc. (“Intensity” or the “Company”) (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the…Read More